Paid Clinical Trials in Colorado
Colorado has 1,870 paid clinical trials enrolling now across cities including Aurora, Denver and Colorado Springs. Search by condition, age, or phase to find compensated research studies accepting participants near you.
Research sites in Colorado include University of Colorado Anschutz and National Jewish Health, running studies across oncology, cardiology, neurology, and more. The most actively recruiting conditions are Breast Cancer, Multiple Myeloma, Colorectal Cancer, Advanced Solid Tumor — browse the full list or use the filters to match your diagnosis. Both patients and healthy volunteers may qualify. Most studies offer compensation for time and travel.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Colorado
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
Detection of Atrial Fibrillation Using PPG From Smartphone Cameras
Non-invasive Prediction of EArly Cardiac rEjection
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Novel Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
1,648 clinical trials
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Phase 2 Study to Assess the Safety and Efficacy of ANG003
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Study of DONQ52 in Active Celiac Disease
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Common conditions studied in Colorado
- Breast Cancer (30 active studies)
- Multiple Myeloma (24 active studies)
- Colorectal Cancer (23 active studies)
- Advanced Solid Tumor (21 active studies)
- Ovarian Cancer (21 active studies)
- Obesity (20 active studies)
Leading research sponsors in Colorado
- University of Colorado, Denver
- AstraZeneca
- National Cancer Institute (NCI)
- Merck Sharp & Dohme LLC
- VA Office of Research and Development
Frequently asked questions
How many paid clinical trials are currently recruiting in Colorado?
There are approximately 1,870 recruiting clinical trials in Colorado listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Colorado pay participants?
Most recruiting trials in Colorado compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Colorado?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Colorado?
The most common conditions under active study in Colorado include Breast Cancer (30), Multiple Myeloma (24), Colorectal Cancer (23), Advanced Solid Tumor (21), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Colorado?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Colorado on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Colorado?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.